Apremilast (CAS 608141-41-9) Market Report

China Apremilast (CAS 608141-41-9) Industry Market Research Report 2023-2029

  • POSTDATE：Sep 22, 2023
  • PAGES：180
  • REPORT CODE：GMM1812873
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Apremilast, brand name Otezla among others, is a medication for the treatment of certain types of psoriasis and psoriatic arthritis. It may also be useful for other immune system related inflammatory diseases. The drug acts as a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4) and inhibits spontaneous production of TNF-alpha from human rheumatoid synovial cells.It is taken by mouth.

    This report elaborates on the current development of the Apremilast (CAS 608141-41-9) industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • Intas Pharmaceuticals

    • AChemBlock

    • Cayman Chemical

    • Hangzhou Longshine Bio-Tech Co, Ltd

    • Mehta API Pvt Ltd

    • DR REDDYS LABORATORIES LTD

    • Lupin Ltd

    • Otezla

    • Zhejiang Ausun Pharmaceutical

    By Type:

    • Solid

    • Liquid

    By Application:

    • Psoriatic arthritis

    • Psoriasis

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China Apremilast (CAS 608141-41-9) Market Overview 2018-2029

    • 1.1 China Apremilast (CAS 608141-41-9) Industry Development Overview

    • 1.2 China Apremilast (CAS 608141-41-9) Industry Development History

    • 1.3 China Apremilast (CAS 608141-41-9) Industry Market Size (2018-2029)

    • 1.4 China Apremilast (CAS 608141-41-9) Market Analysis by Type from Production Side

      • 1.4.1 China Apremilast (CAS 608141-41-9) Production Volume, Production Value and Growth Rate of Solid (2018-2029)

      • 1.4.2 China Apremilast (CAS 608141-41-9) Production Volume, Production Value and Growth Rate of Liquid (2018-2029)

    • 1.5 China Apremilast (CAS 608141-41-9) Market Analysis by Application from Consumption End

      • 1.5.1 China Apremilast (CAS 608141-41-9) Sales Volume, Sales Value and Growth Rate of Psoriatic arthritis (2018-2029)

      • 1.5.2 China Apremilast (CAS 608141-41-9) Sales Volume, Sales Value and Growth Rate of Psoriasis (2018-2029)

    • 1.6 China Apremilast (CAS 608141-41-9) Market Analysis by Region

      • 1.6.1 North China Apremilast (CAS 608141-41-9) Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China Apremilast (CAS 608141-41-9) Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China Apremilast (CAS 608141-41-9) Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China Apremilast (CAS 608141-41-9) Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China Apremilast (CAS 608141-41-9) Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China Apremilast (CAS 608141-41-9) Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China Apremilast (CAS 608141-41-9) Market Size and Growth Rate from 2018-2029

    Chapter 2 China Apremilast (CAS 608141-41-9) Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on Apremilast (CAS 608141-41-9) Market Status and Competition at home and abroad in 2023

      • 2.2.2 China Apremilast (CAS 608141-41-9) Market Status and Competition Analysis in 2023

      • 2.2.3 China Apremilast (CAS 608141-41-9) Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China Apremilast (CAS 608141-41-9) Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on Apremilast (CAS 608141-41-9) Industry Development

    Chapter 3 Apremilast (CAS 608141-41-9)Industry Chain Analysis

    • 3.1 Apremilast (CAS 608141-41-9) Industry Chain

    • 3.2 Apremilast (CAS 608141-41-9) Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the Apremilast (CAS 608141-41-9) Market

    • 3.3 Apremilast (CAS 608141-41-9) Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the Apremilast (CAS 608141-41-9) Market

    Chapter 4 China Apremilast (CAS 608141-41-9) Market, by Type

    • 4.1 China Apremilast (CAS 608141-41-9) Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China Apremilast (CAS 608141-41-9) Total Production Volume and Growth Rate from Production Side

    • 4.5 China Apremilast (CAS 608141-41-9) Production Volume and Growth Rate, by Type

      • 4.5.1 China Apremilast (CAS 608141-41-9) Production Volume and Growth Rate of Solid

      • 4.5.2 China Apremilast (CAS 608141-41-9) Production Volume and Growth Rate of Liquid

    Chapter 5 China Apremilast (CAS 608141-41-9) Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China Apremilast (CAS 608141-41-9) Total Market Size and Growth Rate from Consumption End

    • 5.5 China Apremilast (CAS 608141-41-9) Market Size and Growth Rate, by Application

      • 5.5.1 China Apremilast (CAS 608141-41-9) Market Size and Growth Rate of Psoriatic arthritis

      • 5.5.2 China Apremilast (CAS 608141-41-9) Market Size and Growth Rate of Psoriasis

    Chapter 6 China Apremilast (CAS 608141-41-9) Market, by Region

    • 6.1 China Apremilast (CAS 608141-41-9) Production Volume and Production Value, by Region

    • 6.2 China Apremilast (CAS 608141-41-9) Sales Volume and Sales Value, by Region

    Chapter 7 North China Apremilast (CAS 608141-41-9) Market Analysis

    • 7.1 North China Apremilast (CAS 608141-41-9) Market, by Type

    • 7.2 North China Apremilast (CAS 608141-41-9) Market, by Application

    Chapter 8 Central China Apremilast (CAS 608141-41-9) Market Analysis

    • 8.1 Central China Apremilast (CAS 608141-41-9) Market, by Type

    • 8.2 Central China Apremilast (CAS 608141-41-9) Market, by Application

    Chapter 9 South China Apremilast (CAS 608141-41-9) Market Analysis

    • 9.1 South China Apremilast (CAS 608141-41-9) Market, by Type

    • 9.2 South China Apremilast (CAS 608141-41-9) Market, by Application

    Chapter 10 East China Apremilast (CAS 608141-41-9) Market Analysis

    • 10.1 East China Apremilast (CAS 608141-41-9) Market, by Type

    • 10.2 East China Apremilast (CAS 608141-41-9) Market, by Application

    Chapter 11 Northeast China Apremilast (CAS 608141-41-9) Market Analysis

    • 11.1 Northeast China Apremilast (CAS 608141-41-9) Market, by Type

    • 11.2 Northeast China Apremilast (CAS 608141-41-9) Market, by Application

    Chapter 12 Southwest China Apremilast (CAS 608141-41-9) Market Analysis

    • 12.1 Southwest China Apremilast (CAS 608141-41-9) Market, by Type

    • 12.2 Southwest China Apremilast (CAS 608141-41-9) Market, by Application

    Chapter 13 Northwest China Apremilast (CAS 608141-41-9) Market Analysis

    • 13.1 Northwest China Apremilast (CAS 608141-41-9) Market, by Type

    • 13.2 Northwest China Apremilast (CAS 608141-41-9) Market, by Application

    Chapter 14 Company Profiles

      • 14.1 Intas Pharmaceuticals

        • 14.1.1 Intas Pharmaceuticals Company Profile

        • 14.1.2 Intas Pharmaceuticals Apremilast (CAS 608141-41-9) Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 AChemBlock

        • 14.2.1 AChemBlock Company Profile

        • 14.2.2 AChemBlock Apremilast (CAS 608141-41-9) Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 Cayman Chemical

        • 14.3.1 Cayman Chemical Company Profile

        • 14.3.2 Cayman Chemical Apremilast (CAS 608141-41-9) Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 Hangzhou Longshine Bio-Tech Co, Ltd

        • 14.4.1 Hangzhou Longshine Bio-Tech Co, Ltd Company Profile

        • 14.4.2 Hangzhou Longshine Bio-Tech Co, Ltd Apremilast (CAS 608141-41-9) Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 Mehta API Pvt Ltd

        • 14.5.1 Mehta API Pvt Ltd Company Profile

        • 14.5.2 Mehta API Pvt Ltd Apremilast (CAS 608141-41-9) Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 DR REDDYS LABORATORIES LTD

        • 14.6.1 DR REDDYS LABORATORIES LTD Company Profile

        • 14.6.2 DR REDDYS LABORATORIES LTD Apremilast (CAS 608141-41-9) Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 Lupin Ltd

        • 14.7.1 Lupin Ltd Company Profile

        • 14.7.2 Lupin Ltd Apremilast (CAS 608141-41-9) Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 Otezla

        • 14.8.1 Otezla Company Profile

        • 14.8.2 Otezla Apremilast (CAS 608141-41-9) Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 Zhejiang Ausun Pharmaceutical

        • 14.9.1 Zhejiang Ausun Pharmaceutical Company Profile

        • 14.9.2 Zhejiang Ausun Pharmaceutical Apremilast (CAS 608141-41-9) Market Performance

        • 14.9.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 Apremilast (CAS 608141-41-9) Industry Research Conclusions

    • 15.2 Apremilast (CAS 608141-41-9) Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China Apremilast (CAS 608141-41-9) Industry Market Size (2018-2029)

    • Figure China Apremilast (CAS 608141-41-9) Production Volume, Production Value and Growth Rate of Solid (2018-2029)

    • Figure China Apremilast (CAS 608141-41-9) Production Volume, Production Value and Growth Rate of Liquid (2018-2029)

    • Figure China Apremilast (CAS 608141-41-9) Sales Volume, Sales Value and Growth Rate of Psoriatic arthritis (2018-2029)

    • Figure China Apremilast (CAS 608141-41-9) Sales Volume, Sales Value and Growth Rate of Psoriasis (2018-2029)

    • Figure North China Apremilast (CAS 608141-41-9) Market Size and Growth Rate from 2018-2029

    • Figure Central China Apremilast (CAS 608141-41-9) Market Size and Growth Rate from 2018-2029

    • Figure South China Apremilast (CAS 608141-41-9) Market Size and Growth Rate from 2018-2029

    • Figure East China Apremilast (CAS 608141-41-9) Market Size and Growth Rate from 2018-2029

    • Figure Northeast China Apremilast (CAS 608141-41-9) Market Size and Growth Rate from 2018-2029

    • Figure Southwest China Apremilast (CAS 608141-41-9) Market Size and Growth Rate from 2018-2029

    • Figure Northwest China Apremilast (CAS 608141-41-9) Market Size and Growth Rate from 2018-2029

    • Figure Apremilast (CAS 608141-41-9) Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China Apremilast (CAS 608141-41-9) Market Share by Type in 2018

    • Figure China Apremilast (CAS 608141-41-9) Market Share by Type in 2023

    • Figure China Apremilast (CAS 608141-41-9) Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China Apremilast (CAS 608141-41-9) Production Volume and Growth Rate of Solid (2018-2023)

    • Figure China Apremilast (CAS 608141-41-9) Production Volume and Growth Rate of Liquid (2018-2023)

    • Figure China Apremilast (CAS 608141-41-9) Market Share by Application in 2018

    • Figure China Apremilast (CAS 608141-41-9) Market Share by Application in 2023

    • Figure China Apremilast (CAS 608141-41-9) Total Market Size and Growth Rate from Consumption End

    • Figure China Apremilast (CAS 608141-41-9) Market Size and Growth Rate of Psoriatic arthritis (2018-2023)

    • Figure China Apremilast (CAS 608141-41-9) Market Size and Growth Rate of Psoriasis (2018-2023)

    • Table China Apremilast (CAS 608141-41-9) Production Volume by Region (2018-2023)

    • Table China Apremilast (CAS 608141-41-9) Production Volume Share by Region (2018-2023)

    • Figure China Apremilast (CAS 608141-41-9) Production Volume Share by Region (2018-2023)

    • Table China Apremilast (CAS 608141-41-9) Production Value by Region (2018-2023)

    • Table China Apremilast (CAS 608141-41-9) Production Value Share by Region (2018-2023)

    • Figure China Apremilast (CAS 608141-41-9) Production Value Share by Region (2018-2023)

    • Table China Apremilast (CAS 608141-41-9) Sales Volume by Region (2018-2023)

    • Table China Apremilast (CAS 608141-41-9) Sales Volume Share by Region (2018-2023)

    • Figure China Apremilast (CAS 608141-41-9) Sales Volume Share by Region (2018-2023)

    • Table China Apremilast (CAS 608141-41-9) Sales Value by Region (2018-2023)

    • Table China Apremilast (CAS 608141-41-9) Sales Value Share by Region (2018-2023)

    • Figure China Apremilast (CAS 608141-41-9) Sales Value Share by Region (2018-2023)

    • Table North China Apremilast (CAS 608141-41-9) Production Volume by Type (2018-2023)

    • Table North China Apremilast (CAS 608141-41-9) Production Volume Share by Type (2018-2023)

    • Figure North China Apremilast (CAS 608141-41-9) Production Volume Share by Type (2018-2023)

    • Table North China Apremilast (CAS 608141-41-9) Sales Volume by Application (2018-2023)

    • Table North China Apremilast (CAS 608141-41-9) Sales Volume Share by Application (2018-2023)

    • Figure North China Apremilast (CAS 608141-41-9) Sales Volume Share by Application (2018-2023)

    • Table Central China Apremilast (CAS 608141-41-9) Production Volume by Type (2018-2023)

    • Table Central China Apremilast (CAS 608141-41-9) Production Volume Share by Type (2018-2023)

    • Figure Central China Apremilast (CAS 608141-41-9) Production Volume Share by Type (2018-2023)

    • Table Central China Apremilast (CAS 608141-41-9) Sales Volume by Application (2018-2023)

    • Table Central China Apremilast (CAS 608141-41-9) Sales Volume Share by Application (2018-2023)

    • Figure Central China Apremilast (CAS 608141-41-9) Sales Volume Share by Application (2018-2023)

    • Table South China Apremilast (CAS 608141-41-9) Production Volume by Type (2018-2023)

    • Table South China Apremilast (CAS 608141-41-9) Production Volume Share by Type (2018-2023)

    • Figure South China Apremilast (CAS 608141-41-9) Production Volume Share by Type (2018-2023)

    • Table South China Apremilast (CAS 608141-41-9) Sales Volume by Application (2018-2023)

    • Table South China Apremilast (CAS 608141-41-9) Sales Volume Share by Application (2018-2023)

    • Figure South China Apremilast (CAS 608141-41-9) Sales Volume Share by Application (2018-2023)

    • Table East China Apremilast (CAS 608141-41-9) Production Volume by Type (2018-2023)

    • Table East China Apremilast (CAS 608141-41-9) Production Volume Share by Type (2018-2023)

    • Figure East China Apremilast (CAS 608141-41-9) Production Volume Share by Type (2018-2023)

    • Table East China Apremilast (CAS 608141-41-9) Sales Volume by Application (2018-2023)

    • Table East China Apremilast (CAS 608141-41-9) Sales Volume Share by Application (2018-2023)

    • Figure East China Apremilast (CAS 608141-41-9) Sales Volume Share by Application (2018-2023)

    • Table Northeast China Apremilast (CAS 608141-41-9) Production Volume by Type (2018-2023)

    • Table Northeast China Apremilast (CAS 608141-41-9) Production Volume Share by Type (2018-2023)

    • Figure Northeast China Apremilast (CAS 608141-41-9) Production Volume Share by Type (2018-2023)

    • Table Northeast China Apremilast (CAS 608141-41-9) Sales Volume by Application (2018-2023)

    • Table Northeast China Apremilast (CAS 608141-41-9) Sales Volume Share by Application (2018-2023)

    • Figure Northeast China Apremilast (CAS 608141-41-9) Sales Volume Share by Application (2018-2023)

    • Table Southwest China Apremilast (CAS 608141-41-9) Production Volume by Type (2018-2023)

    • Table Southwest China Apremilast (CAS 608141-41-9) Production Volume Share by Type (2018-2023)

    • Figure Southwest China Apremilast (CAS 608141-41-9) Production Volume Share by Type (2018-2023)

    • Table Southwest China Apremilast (CAS 608141-41-9) Sales Volume by Application (2018-2023)

    • Table Southwest China Apremilast (CAS 608141-41-9) Sales Volume Share by Application (2018-2023)

    • Figure Southwest China Apremilast (CAS 608141-41-9) Sales Volume Share by Application (2018-2023)

    • Table Northwest China Apremilast (CAS 608141-41-9) Production Volume by Type (2018-2023)

    • Table Northwest China Apremilast (CAS 608141-41-9) Production Volume Share by Type (2018-2023)

    • Figure Northwest China Apremilast (CAS 608141-41-9) Production Volume Share by Type (2018-2023)

    • Table Northwest China Apremilast (CAS 608141-41-9) Sales Volume by Application (2018-2023)

    • Table Northwest China Apremilast (CAS 608141-41-9) Sales Volume Share by Application (2018-2023)

    • Figure Northwest China Apremilast (CAS 608141-41-9) Sales Volume Share by Application (2018-2023)

    • Table Intas Pharmaceuticals Company Profile

    • Table Intas Pharmaceuticals Apremilast (CAS 608141-41-9) Revenue, Price and Gross (2018-2023)

    • Table AChemBlock Company Profile

    • Table AChemBlock Apremilast (CAS 608141-41-9) Revenue, Price and Gross (2018-2023)

    • Table Cayman Chemical Company Profile

    • Table Cayman Chemical Apremilast (CAS 608141-41-9) Revenue, Price and Gross (2018-2023)

    • Table Hangzhou Longshine Bio-Tech Co, Ltd Company Profile

    • Table Hangzhou Longshine Bio-Tech Co, Ltd Apremilast (CAS 608141-41-9) Revenue, Price and Gross (2018-2023)

    • Table Mehta API Pvt Ltd Company Profile

    • Table Mehta API Pvt Ltd Apremilast (CAS 608141-41-9) Revenue, Price and Gross (2018-2023)

    • Table DR REDDYS LABORATORIES LTD Company Profile

    • Table DR REDDYS LABORATORIES LTD Apremilast (CAS 608141-41-9) Revenue, Price and Gross (2018-2023)

    • Table Lupin Ltd Company Profile

    • Table Lupin Ltd Apremilast (CAS 608141-41-9) Revenue, Price and Gross (2018-2023)

    • Table Otezla Company Profile

    • Table Otezla Apremilast (CAS 608141-41-9) Revenue, Price and Gross (2018-2023)

    • Table Zhejiang Ausun Pharmaceutical Company Profile

    • Table Zhejiang Ausun Pharmaceutical Apremilast (CAS 608141-41-9) Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US